×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ATOS – atossa therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ATOS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/20
11:27 am
atos
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
Medium
Report
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? [Yahoo! Finance]
12/12
12:37 pm
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its "buy" rating re-affirmed by analysts at HC Wainwright.
12/12
08:15 am
atos
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
Medium
Report
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
12/11
08:15 am
atos
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
Medium
Report
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
12/10
09:22 am
atos
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]
Low
Report
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]
12/10
09:05 am
atos
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
Neutral
Report
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
12/9
08:15 am
atos
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
Low
Report
Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research
12/9
08:11 am
atos
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.50 to $7.00. They now have a "buy" rating on the stock.
Low
Report
Atossa Therapeutics, Inc. (NASDAQ: ATOS) had its price target raised by analysts at Ascendiant Capital Markets from $6.50 to $7.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Headline
Impact
12/10
09:05 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Dec 10
Neutral
Report
Form 8-K ATOSSA THERAPEUTICS, For: Dec 10
11/19
04:35 pm
atos
Form 8-K ATOSSA THERAPEUTICS, For: Nov 19
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Nov 19
11/19
04:30 pm
atos
Form 424B5 ATOSSA THERAPEUTICS,
Medium
Report
Form 424B5 ATOSSA THERAPEUTICS,
11/12
01:33 pm
atos
Form SC 13G/A ATOSSA THERAPEUTICS, Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A ATOSSA THERAPEUTICS, Filed by: VANGUARD GROUP INC
11/12
09:42 am
atos
Form 10-Q ATOSSA THERAPEUTICS, For: Sep 30
Medium
Report
Form 10-Q ATOSSA THERAPEUTICS, For: Sep 30
11/12
09:27 am
atos
Form 8-K ATOSSA THERAPEUTICS, For: Nov 12
Medium
Report
Form 8-K ATOSSA THERAPEUTICS, For: Nov 12
11/8
02:20 pm
atos
Form SC 13G ATOSSA THERAPEUTICS, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G ATOSSA THERAPEUTICS, Filed by: BlackRock, Inc.
11/4
11:28 am
atos
Form SC 13G/A ATOSSA THERAPEUTICS, Filed by: VANGUARD GROUP INC
Neutral
Report
Form SC 13G/A ATOSSA THERAPEUTICS, Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/27
Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density
22.9%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
3/30 New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients 10.3%
4/17 COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted 9.0%
10/16 Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology 7.6%
3/13 Atossa to meet with FDA on Endoxifen development [Seeking Alpha] 7.1%
5/21 Form 4 ATOSSA GENETICS INC For: May 17 Filed by: Steinhart Richard I 5.9%
3/26 Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update 4.8%
5/30 Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019 4.0%
4/13 Form 4 ATOSSA THERAPEUTICS, For: Apr 09 Filed by: Guse Kyle 3.4%
12/18 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. 2.5%
TOP News Decliners
4/16
Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
-26.0%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
7/11 Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated -24.8%
4/27 Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study -21.9%
4/20 Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study -17.0%
5/13 Form 8-K ATOSSA GENETICS INC For: May 13 -10.6%
12/19 Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women -8.4%
4/2 Atossa Therapeutics Announces Clinical Progress -7.8%
6/27 Atossa Genetics Inc (NASDAQ: ATOS) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -4.9%
11/13 Form 10-Q ATOSSA GENETICS INC For: Sep 30 -4.7%
8/13 Q2/2019 6/30/2019 EPS -0.800 ZacksConsensus N/A ActVsEst N/A - N/A -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: